Cerebellar syndrome associated with adaptor protein 3B2-IgG following pembrolizumab treatment for metastatic adenocarcinoma of the lung

Read full text Summarise with VIRAT
Authors: Julia Kucka, Veit Rothhammer, Florian T Nickel, Konstantin Huhn, Dominik Madžar
Cited by: 0
References: 10

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

ABSTRACT Background Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a broad spectrum of neurological immune-related complications. These include paraneoplastic neurological syndromes (PNS), which may be unmasked or triggered by ICIs, as well as direct immune-mediated neurotoxicity, potentially occurring in the absence of identifiable neural antibodies. ICI-associated PNS may involve antibodies overlapping with those seen in spontaneous PNS, although clinical presentations can differ, and ongoing research continues to identify novel neural antibodies. Antibodies against adaptor protein 3 subunit B2 (AP3B2) have recently been implicated in neurological disease. However, they have not previously been reported in ICI-associated neurological syndromes. Conclusion This case expands the spectrum of neural antibodies associated with ICI treatment and supports the concept that ICIs may unmask rare or previously unrecognized autoimmune neurological responses. Although AP3B2 is not traditionally considered a classical PNS marker, its detection in this context highlights the evolving immunological landscape of ICI-associated neurological disease. Therapeutic management remains challenging, with many patients demonstrating limited or transient responses to immunosuppression. Case report We report a 61-year-old man who developed a rapidly progressive cerebellar syndrome leading to immobility after two cycles of pembrolizumab. Cerebrospinal fluid analysis revealed lymphocytic pleocytosis, elevated protein levels, and cerebrospinal fluid–restricted oligoclonal bands. Antibodies against AP3B2 were detected in both serum and cerebrospinal fluid, along with additional antibodies targeting unknown antigens expressed in rat and monkey hippocampal and cerebellar tissue. Brain MRI was unremarkable. High-dose corticosteroid treatment resulted in only transient clinical improvement.

Fields of Study & Subjects

Autoimmune Neurological Disorders and Treatments Cancer Immunotherapy and Biomarkers Peripheral Neuropathies and Disorders

Publication details

Journal / source
Neuroimmunology Reports
Volume
9
Pages
100282–100282
Publication date
23 March 2026
Language
EN